Please login to the form below
Sangamo
This page shows the latest Sangamo news and features for those working in and with pharma, biotech and healthcare.
Biogen strikes $800m deal to buy gene therapy firm Nightstar
For Biogen, the deal bolsters its position in gene therapy – a category it has been steadily building since around 2014 when it formed an alliance with Sangamo – and also “accelerates our
Latest news
-
Roche buys gene therapy specialist Spark for $4.3bn
at the moment, and UniQure and Pfizer/Sangamo both ushering haemophilia B therapies through pivotal trials.
-
BioMarin prepares for haemophilia A gene therapy data readout, filing
The company has rivals close behind it – Spark and Pfizer and Sangamo, but BioMarin could gain the upper hand this year if its data is robust. ... This could see Valrox reach the market by 2020, which should put it significantly ahead of rival products
-
Trial dents confidence in Sangamo’s gene-editing tech
Company proposing switch to next-gen version. Shares in US biotech Sangamo have slumped after the company revealed a trial of a drug based on its gene-editing technology failed to ... Sangamo said that interim results from the phase 1/2 CHAMPIONS study
-
Roche's O’Day swaps big pharma for big biotech
with Sangamo to use its zinc finger gene-editing platform for drug discovery, and a $1.2bn deal to acquire Nimbus Therapeutics and its non-alcoholic steatohepatitis (NASH) candidate selonsertib.
-
Sangamo’s first gene-editing trial doesn’t convince investors
Market spooked by inconclusive early results. Sangamo Therapeutics has claimed a first with a trial of its genome-editing technology for rare disease Hunter syndrome, but the data didn’t convince ... Elaprase costs hundreds of thousands of dollars per
More from news
Approximately 7 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
2019: CRISPR and therapeutic gene editing comes of age
Editas, and the failure of Sangamo Therapeutics’ rival zinc-finger nucleases (ZFNs) platform. ... Editas, CRISPR, Sangamo, Cellectis/Allogene and their peers to take the slow road to proving that gene- editing can deliver safe and effective
-
The handover: Pfizer reshapes itself for a new era
It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.
-
Deal Watch table for January 2014
320. Sangamo/Biogen Idec . Collaboration and licence. Development of therapies for haemoglobinopathies using zinc finger genome editing.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Eric Rhodes becomes CEO of ERS Genomics
Prior to joining Horizon Discovery, Rhodes held a number of senior positions including director of business development at Sigma-Aldrich and vice president of business development and alliance management at Sangamo
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Health Consultant - Brand Comms
-
Competitive Salary
- Scientific Director – Medical Communications
-
Salary TBC
-
Senior Medical Writer
-
Salary TBC
- Home-based Senior Medical Writer – Med Ed
-
Salary TBC
-
Creative/ Medical Writer
-
Circa £35, 000 With Benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
- Senior Account Manager, Medical Communications, London
-
Excellent package
- EU Head of Business Development and Client Service
-
Exceptional packge and bonus
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Associate Director – Social Healthcare – London
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
Subscribe to our email news alerts
PMHub
Dovetail
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- 50 questions for delivering an exceptional healthcare brand experience
- Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
- The brand strategy revolution
- Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
